March 23, 2017 | 11 am to 11:30 am EDT

Sponsored by

Webinar Description:

Proliferation biomarkers play a key role in monitoring malignancies, aiding making prognoses and providing early insight into the effects of therapy.

Thymidine kinase 1 (TK1) is a well-known proliferation biomarker but most current methods are based on enzyme activity methods and may under-estimate serum TK1 levels, particularly in subjects with solid tumors

The AroCell TK210 ELISA brings the sensitivity and robustness of immunoassay to this important biomarker.

Data will be presented on the value of the AroCell TK210 ELISA in the study of a range of hematological and solid tumors

Learning Objectives:

• Role of Proliferation Biomarkers
• A Review of Thymidine Kinase 1 as a Proliferation Biomarker
• Improved Immunoassay of TK1 based on the TK210 antigen – AroCell TK 210 ELISA
• Monitoring of Proliferative Disease using the AroCell TK210 ELISA
• Synergistic Combination of Tk210 ELISA with other Tumor Markers

Speakers:

Staffan Eriksson is Professor in Medical and Physiological Chemistry at the Swedish University of Agricultural Sciences. Professor Eriksson has been active in the research of medical biochemistry and Thymidine Kinase for many decades, and has published over 120 scientific studies related to these topics. He is also a founder of AroCell AB and one of the inventors of the TK 210 ELISA test for measuring cell growth and turnover. 

Martin Shaw has had long experience in the development and application of many novel biomarkers. He has participated in industry-wide consortia on the qualification of biomarkers for application in pre-clinical and clinical trials. He has spoken at many congresses including being a guest speaker at the FDA.